MannKind secures $50M financing and FDA approval for Furoscix ReadyFlow auto‑injector

MannKind Furoscix ReadyFlow auto‑injector $50 million financing FDA approval

MannKind Corporation announced a $50 million private placement led by Frazier Life Sciences, with proceeds earmarked for general corporate purposes and a $45 million contingent‑value‑rights payment triggered by regulatory approval. The same day, the U.S. Food and Drug Administration approved MannKind’s Furoscix ReadyFlow auto‑injector, a subcutaneous furosemide device that delivers an 80 mg/mL dose in under 10 seconds and provides IV‑equivalent exposure for treating edema in adults with heart failure or chronic kidney disease. CEO Michael Castagna said the approval “marks an important milestone” for patients and the healthcare system, while Dr. Hunter Champion highlighted the at‑home option’s potential to reduce emergency visits and hospitalisations. Furoscix ReadyFlow is slated for commercial launch in the United States by August 2026, offering a faster alternative to the existing on‑body infusor.

Sources

MannKind raises $50M, wins FDA nod for Furoscix auto-injector [www.drugdeliverybusiness.com]

14 days ago

MNKD Stock Rises 8% On Furoscix ReadyFlow Approval And $50M Funding Boost [newsable.asianetnews.com]

13 days ago

FDA Approves Furosemide Injection (Furoscix ReadyFlow) for Edema in HF, CKD [www.consultantlive.com]

14 days ago

MannKind Corporation (MNKD) Discusses FDA Approval of Furoscix ReadyFlow for IV-Equivalent Diuretic Therapy in Fluid Overload Transcript | Seeking Alpha [seekingalpha.com]

14 days ago